High PSMA expression is associated with immunosuppressive tumor microenvironment in clear cell renal cell carcinoma

Author contributions

P.J.V.: conceptualization, data curation, methodology, visualization, writing-original draft-review and editing, and supervision. A.K.: data curation, visualization, and writing—original draft. I.Z.: methodology, writing—review and editing. V.T.: writing—review and editing, and supervision. All authors have read and agreed to the published version of the manuscript. All authors were involved in manuscript editing and manuscript review.

Conflict of interest

None declared.

The data that support the findings of this study are available at https://www.cbioportal.org/study/summary?id=kirc_tcga_pan_can_atlas_2018, accessed on 27 January 2024.

References

[1] Baccala A, Sercia L, Li J et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007;70:385-90. https://doi.org/10.1016/j.urology.2007.03.025.

[2] Muselaers S, Erdem S, Bertolo R et al. PSMA PET/CT in renal cell carcinoma: an overview of current literature. J Clin Med 2022;11:1829. https://doi.org/10.3390/jcm11071829.

[3] Spatz S, Tolkach Y, Jung K et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol 2018;199:370-7. https://doi.org/10.1016/j.juro.2017.08.079.

[4] Bui VN, Unterrainer LM, Brendel M et al. PSMA-expression is highly associated with histological subtypes of renal cell carcinoma: potential implications for theranostic approaches. Biomedicines 2023;11:3095. https://doi.org/10.3390/biomedicines11113095.

[5] Li Y, Zheng R, Zhang Y et al. Special issue "the advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer 2023;152:42-50. https://doi.org/10.1002/ijc.34189.

[6] Raveenthiran S, Esler R, Yaxley J et al. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:2280-8. https://doi.org/10.1007/s00259-019-04432-2.

[7] Seront E, Lhommel R, Tombal B. Case report:early 68Ga-PSMAPET metabolic assessment and response to systemic treatment for first-line metastatic clear cell renal cell carcinoma; about two clinical cases. Front Oncol 2021;11:782166. https://doi.org/10.3389/fonc.2021.782166.

[8] Gao J, Meng L, Xu Q et al. 68Ga-PSMA-11 PET/CT parameter correlates with pathological VEGFR-2/PDGFR-βexpression in renal cell carcinoma patients. Mol Imaging Biol 2022;24:759-68. https://doi.org/10.1007/s11307-022-01725-1.

[9] Meng L, Zhang S, Gao J et al. [68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF- 2α expression and therapeutic response to HIF- 2α antagonists in patients with RCC. Eur Radiol 2022;32:6545-53. https://doi.org/10.1007/s00330-022-08738-y.

[10] Wang B, Deng Y, Xu Q et al. Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clin Radiol 2023;78:e417-24. https://doi.org/10.1016/j.crad.2023.01.003.